Skip to main content
. 2023 Feb 5;13(4):1264–1285. doi: 10.7150/thno.81860

Figure 5.

Figure 5

(A) Schematics of the preparation, action mechanism, and therapeutic effects of 3D-cultured MSC-EVs in AD therapy. Ref. 157. (B) Schematics of the use of miR-29-loaded MSC-derived exosomes in AD therapy. (C) The escape latency, total errors, distance, and mean velocity of AD mice after transplantation of the engineered MSC-EVs containing miR-29b. Reproduced from ref. 56. Copyright © 2020 Yavar Jahangard et al. (D) BACE-1 expression in the hippocampus. Reproduced from ref. 65. Copyright © 2021 HyeJu Jeong et al. (E) The swimming path of the mice in Morris water maze test. (F) The change of NEP level in hUCMSC-EVs. (G) Schematics of the preparation, action mechanism, and therapeutic effects of NEP mRNA- and protein-loaded MSC-EVs in AD therapy. (H) The colocalisation of CD63 and CD81-positive hUCMSC-EVs in the hippocampus. Reproduced from ref. 65. Copyright © 2021 HyeJu Jeong et al.

HHS Vulnerability Disclosure